Triptans News and Research

RSS

The mechanisms of triptan using metabolomics and transcriptomics in spontaneous migraine attacks

Researchers discuss the mechanisms of triptans for the treatment of spontaneous migraine attacks by using transcriptomics and metabolomics.

3 Aug 2023

Redefining menstrual migraines: New criteria for accurate diagnosis and improved treatment response

Menstrual migraine, a specific type of migraine affecting women, leads to significant disability and impacts the quality of life during reproductive stages. Understanding its prevalence and impact is crucial for effective management.

17 May 2023

Guidance for diagnosing and managing migraine

Migraine is a major cause of disability, affecting about 12% of people. A 2-part series published in CMAJ (Canadian Medical Association Journal) on diagnosing and managing the condition with both acute and preventive therapy provides guidance for clinicians.

30 Jan 2023

Exploring methods to speed up the relief of migraine medications

In order for migraine medication to be effective, it is vital that the active substance is released into the bloodstream immediately.

26 Jan 2023

Commonly prescribed class of migraine drugs may be effective in treating obesity

Triptans, a commonly prescribed class of migraine drugs, may also be useful in treating obesity, a new study by scientists at UT Southwestern suggests.

11 Jul 2022

Case study examines prescriptions and healthcare use in non-hospitalized COVID-19 recoverers

In a new study published in The Lancet, a team of researchers examined prescription drug and healthcare use after SARS-CoV-2 infection in those who did not require hospital admission.

12 May 2021

People suffering from cluster headache often face a long delay in being diagnosed properly

New research led by Keele University has found that people suffering from cluster headache often face a long delay in being diagnosed correctly.

2 Jun 2020

New neuromodulation device may help prevent migraine

If your bank account balance looks nail-bitingly low and you won't get paid for days, you might agonize over every dollar you spend. Maybe you'll scrutinize grocery-store ads more closely than usual or brew your own coffee instead of ordering it from a barista.

24 Jan 2020

New drug 'ubrogepant' may work for migraine

A new study published in the November 19, 2019 issue of JAMA shows that a newly developed small molecule drug called ubrogepant may successfully fight migraine at doses of 25 and 50 mg, with pain relief at 2 hours with both doses, while the most troublesome symptom of migraine was held off at 2 hours post-dose with the 50 mg dose. This may help millions of migraine patients to achieve pain relief and function better.

19 Nov 2019

New AAN guidelines includes recommendations for treatment of migraine in children, teens

For children and teens with migraine, the pain and symptoms that accompany migraine attacks can be debilitating, resulting in missed school days, absence from social or sporting events, and affected home activities.

14 Aug 2019

Survey shows increasing use of opioids to treat migraine headaches

An increasing number of Americans are using opioids to treat their migraine headaches, despite the fact that opioids are not the recommended first-line therapy for migraine in most cases.

7 Aug 2019

New drug for acute migraine shows promising results in a large-scale trial

A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine.

11 Jul 2019

Hottest pepper gives man “thunderclap”

An unidentified 34 year old man reportedly ate a Carolina Reaper – one of the hottest rates peppers in the world, during a contest. What followed was a series of intense headaches and retching in the man. The headaches are typically termed 'thunderclap headaches'. The case study was published this week by the doctors attending the man in the journal BMJ Case Reports.

10 Apr 2018

Cluster headaches: searching for effective therapies

Cluster headaches are probably the most painful types of pain a human can suffer and it is for no small reason that this condition is also sometimes referred to as suicide headache.

25 May 2017

Study may open door to developing cure for headache during flight

Many people suffer from pain when they fly but that may soon be a thing of the past. A new study from Aalborg University may have discovered the mechanisms responsible, opening the door to developing a cure.

6 Mar 2017

Worsening migraine no reason to halt dihydroergotamine infusion

Worsening of headache during intravenous dihydroergotamine treatment for chronic migraine does not mean that the therapy will be unsuccessful, say researchers.

12 Feb 2016

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

CGRP monoclonal antibodies show promise in treating migraine

Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating high-frequency episodic migraine and chronic migraine.

17 Jun 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

AHS provides updated assessment of treatments for acute migraine

The January issue of the American Headache Society journal Headache provides an updated assessment of the best treatments to use when a migraine attack occurs. The assessment will form the basis of new AHS treatment guidelines.

21 Jan 2015